Noam Bercovich

VP, Development at ADVA Biotechnologies

Mr. Bercovich has over 19 years of cell therapy development and cGMP experience with extensive expertise in Bioreactor development. Mr. Bercovich was the former VP of Development of Atvio Biotech and the former Director of Process Engineering at Pluristem Therapeutics. Mr. Bercovich’s vast and unique knowledge and experience in cell therapy bioreactor development and cGMP manufacturing is a critical asset for the company.

Links


Org chart

No direct reports

Teams


Offices

This person is not in any offices


ADVA Biotechnologies

ADVA Biotechnology develops enabling technologies for cell therapy manufacturing. The company has developed ADVA X3, a robust, modular cell-manufacturing cGMP system based on a single-use end-to-end solution.ADVA X3 enables autologous cell therapy manufacturing at the bedside, allowing optimization, tight quality assurance, improved availability,reduced time to market, and significant cost reduction. The automated platform is designed to enable autologous manufacturing of additional types of cells with a change in the disposable chamber, allowing efficiency and flexibility with a long pipeline of products.


Industries

Headquarters

Haifa, Israel

Employees

11-50

Links